Under the agreement, Biocon will supply semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive ...

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

As India marks 80 years of the UN, the AIKYAM 2025 event at the UNESCO-listed Ellora caves highlights heritage as the country’s powerful asset ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Under the agreement, Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries Shares of Ajanta ...

Semalutide improves glycaemic control in adults. The product patent expires in most these markets in March 2026. Ajanta ...

Pharmaceutical stocks are back in focus with strong stock-specific triggers. Ajanta Pharma has gained attention after signing a licensing agreement with Biocon to market Semaglutide across 26 ...

Ajanta Pharma partners with Biocon to market Semaglutide in 26 countries, aiming for commercialization after 2026 regulatory approvals.

Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent ...

New Delhi: Biotech firm Biocon on Tuesday said it has signed an out-licensing agreement with Ajanta Pharma to market its ...

Biocon out-licenses its diabetes drug Semaglutide to Ajanta Pharma for export to 23 countries in Africa, Middle East & ...